#120 $AQST FDA Delay Shock The Allergy Drug Setback Investors Missed

Dive into the Aquestive Therapeutics $AQST controversy as we break down a securities class action tied to biotech approvals, FDA delays, and alleged misleading timelines around Anaphylm. This episode is for investors, traders, and anyone following biotech stocks, drug approvals, and market volatility. Expect deep dives, real case analysis, and insights into regulatory risk, clinical setbacks, and stock drops. Visit ZLK.com for more info. Add our WhatsApp Channel We’re not lawyers or accountants, so don’t take this as legal or financial advice.